Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01TBJ
|
|||
| Former ID |
DNCL001882
|
|||
| Drug Name |
CMX-2043
|
|||
| Indication | Cardiac disease [ICD-11: BA00-BE2Z; ICD-10: I00-I99] | Phase 2 | [1] | |
| Myocardial reperfusion injury [ICD-11: NB31] | Phase 2 | [2] | ||
| Company |
Ischemix
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C16H26N2O6S2
|
|||
| Canonical SMILES |
CC(C(=O)O)NC(=O)C(CCC(=O)O)NC(=O)CCCCC1CCSS1
|
|||
| InChI |
1S/C16H26N2O6S2/c1-10(16(23)24)17-15(22)12(6-7-14(20)21)18-13(19)5-3-2-4-11-8-9-25-26-11/h10-12H,2-9H2,1H3,(H,17,22)(H,18,19)(H,20,21)(H,23,24)/t10-,11+,12-/m0/s1
|
|||
| InChIKey |
MQXRTCVZPIHBLD-TUAOUCFPSA-N
|
|||
| CAS Number |
CAS 910627-26-8
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | ClinicalTrials.gov (NCT02103959) Safety and Efficacy of CMX-2043 for Protection of the Heart and Kidneys in Subjects Undergoing Coronary Angiography. U.S. National Institutes of Health. | |||
| REF 3 | Pre-clinical and Clinical Safety Studies of CMX-2043: a cytoprotective lipoic acid analogue for ischaemia-reperfusion injury. Basic Clin Pharmacol Toxicol. 2014 Nov;115(5):456-64. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.